Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.67 |
| ▸ | CTSS | P25774 | 6/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.62 |
| ▸ | CTSL | P07711 | 1/20 | 0.62 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9482703 | 1.00 | ACE (0.67) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL6332454 | 0.93 | ACE (0.68) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL10536264 | 0.89 | ACE (0.70) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL17688687 | 0.89 | ACE (0.70) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL6876021 | 0.89 | ACE (0.63) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL19704254 | 0.89 | ACE (0.63) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL17695878 | 0.89 | ACE (0.63) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL2106430 | 0.89 | ACE (0.63) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL6516027 | 0.86 | ACE (0.70) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL2603668 | 0.86 | ACE (0.70) | ACECTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2023-12-05 | — | — | US | disclosed |
| CN-110234631-B | Composition for treating hypertension and/or fibrosis | 维克特斯生物系统有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20210284612-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-09-16 | — | — | US | disclosed |
| EP-3515895-B1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-08-11 | — | — | EP | disclosed |
| EP-3515895-B1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-07-06 | — | — | US | disclosed |
| EP-3640243-B1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-05-26 | — | — | EP | disclosed |
| EP-3640243-B1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-05-26 | — | — | EP | disclosed |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2020-08-13 | — | — | US | disclosed |
| EP-3515895-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | Vectus Biosystems Limited (AU) | 2019-07-31 | — | — | EP | disclosed |
| US-20190225588-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LTD (AU) | 2019-07-25 | — | — | US | disclosed |
| EP-3207043-B1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10087184-B2 | Dihydropyrrolopyridine inhibitors of RORγ | VITAE PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| WO-2018053588-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-29 | — | — | WO | disclosed |
| US-9796710-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-9481674-B1 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-5026642-A | Process for the enzymatic production of ketones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284612-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | ACE 41/4885CTSS 1582/4885CTSK 1111/4885 |
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | ACE 41/4885CTSS 1582/4885CTSK 1111/4885 |
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | ACE 2763/4885CTSS 4720/4885CTSK 4102/4885 |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | ACE 2752/4885CTSS 4754/4885CTSK 4223/4885 |
| US-10087184-B2 | Dihydropyrrolopyridine inhibitors of RORγ | RORC, RORB, RORA | ACE 2826/4885CTSS 4509/4885CTSK 3906/4885 |
| US-20190225588-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | ACE 41/4885CTSS 1582/4885CTSK 1111/4885 |
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | ACE 41/4885CTSS 1582/4885CTSK 1111/4885 |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | ACE 2763/4885CTSS 4720/4885CTSK 4102/4885 |
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | ACE 41/4885CTSS 1582/4885CTSK 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.